adverse events. Therefore, a detailed con-versation with the patient is needed to make decisions regarding treat-to-target. To help ensure that the recommendations were patient-centered, 2 patients were members of the Voting Panel. While using a treat-to-target approach over not using a treat-to-target approach was discussed by the Voting Panel, we did not address specific targets to be recommended or used. There have been 2 international meetings to discuss potential targets: the use of either disease activity (MDA) or disease activity in psoriatic arthritis (DAPSA) The ACR/NPF PsA guideline conditionally recommends a TNFi biologic over an OSM agent in patients with active PsA. The Strong recommendation supported by moderate-quality evidence, rated down for indirectness. * Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on â‰¥1 of the